These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 2631134)
1. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Teicher MH; Glod CA; Aaronson ST; Gunter PA; Schatzberg AF; Cole JO Psychopharmacol Bull; 1989; 25(4):535-49. PubMed ID: 2631134 [TBL] [Abstract][Full Text] [Related]
2. [Symptoms of DSM IV borderline personality disorder in a nonclinical population of adolescents: study of a series of 35 patients]. Chabrol H; Chouicha K; Montovany A; Callahan S Encephale; 2001; 27(2):120-7. PubMed ID: 11407263 [TBL] [Abstract][Full Text] [Related]
3. Yi-gan san for the treatment of borderline personality disorder: an open-label study. Miyaoka T; Furuya M; Yasuda H; Hayashia M; Inagaki T; Horiguchi J Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):150-4. PubMed ID: 17765378 [TBL] [Abstract][Full Text] [Related]
4. An open trial of valproate in borderline personality disorder. Stein DJ; Simeon D; Frenkel M; Islam MN; Hollander E J Clin Psychiatry; 1995 Nov; 56(11):506-10. PubMed ID: 7592502 [TBL] [Abstract][Full Text] [Related]
5. [Personality disorders in a nonclinical sample of adolescents]. Chabrol H; Chouicha K; Montovany A; Callahan S; Duconge E; Sztulman H Encephale; 2002; 28(6 Pt 1):520-4. PubMed ID: 12506264 [TBL] [Abstract][Full Text] [Related]
6. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
7. Quetiapine in patients with borderline personality disorder: an open-label trial. Adityanjee ; Romine A; Brown E; Thuras P; Lee S; Schulz SC Ann Clin Psychiatry; 2008; 20(4):219-26. PubMed ID: 19034754 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648 [TBL] [Abstract][Full Text] [Related]
9. A relationship between bipolar II disorder and borderline personality disorder? Benazzi F Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1022-9. PubMed ID: 18313825 [TBL] [Abstract][Full Text] [Related]
10. Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission. Zanarini MC; Frankenburg FR; Vujanovic AA; Hennen J; Reich DB; Silk KR Acta Psychiatr Scand; 2004 Dec; 110(6):416-20. PubMed ID: 15521825 [TBL] [Abstract][Full Text] [Related]
12. Gender differences in axis I and axis II comorbidity in patients with borderline personality disorder. Tadić A; Wagner S; Hoch J; Başkaya O; von Cube R; Skaletz C; Lieb K; Dahmen N Psychopathology; 2009; 42(4):257-63. PubMed ID: 19521142 [TBL] [Abstract][Full Text] [Related]
13. Borderline personality disorder characteristics in young adults with recurrent mood disorders: a comparison of bipolar and unipolar depression. Smith DJ; Muir WJ; Blackwood DH J Affect Disord; 2005 Jul; 87(1):17-23. PubMed ID: 15967232 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467 [TBL] [Abstract][Full Text] [Related]
15. Psychosocial functioning of borderline patients and axis II comparison subjects followed prospectively for six years. Zanarini MC; Frankenburg FR; Hennen J; Reich DB; Silk KR J Pers Disord; 2005 Feb; 19(1):19-29. PubMed ID: 15899718 [TBL] [Abstract][Full Text] [Related]
16. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
17. Double-blind study of thioridazine and haloperidol in geriatric patients with a psychosis associated with organic brain syndrome. Cowley LM; Glen RS J Clin Psychiatry; 1979 Oct; 40(10):411-9. PubMed ID: 489517 [TBL] [Abstract][Full Text] [Related]
18. Is bulimia associated with borderline personality disorder? A controlled study. Pope HG; Frankenburg FR; Hudson JI; Jonas JM; Yurgelun-Todd D J Clin Psychiatry; 1987 May; 48(5):181-4. PubMed ID: 3571171 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of phenelzine and haloperidol in borderline personality disorder. Soloff PH; Cornelius J; George A; Nathan S; Perel JM; Ulrich RF Arch Gen Psychiatry; 1993 May; 50(5):377-85. PubMed ID: 8489326 [TBL] [Abstract][Full Text] [Related]
20. Platelet [³H] paroxetine binding in female patients with borderline personality disorder and their sisters. Paris J; Laporte L; Russell J; Ng Ying Kin N; Guttman H Psychiatry Res; 2011 Mar; 186(1):76-9. PubMed ID: 20832123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]